Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26410647.
- Also identified by DOI 10.1016/j.ocl.2015.06.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Historically surgical intervention has been the mainstay of therapy for bone and soft-tissue sarcomas, augmented with adjuvant radiation for local control. Although cytotoxic chemotherapy revolutionized the treatment of many sarcomas, classic treatment regimens are fraught with side effects while outcomes have plateaued. However, since the approval of imatinib in 2002, research into targeted chemotherapy has increased exponentially. With targeted therapies comes the potential for decreased side effects and more potent, personalized treatment options. This article reviews the evolution of medical knowledge regarding sarcoma, the basic science of sarcomatogenesis, and the major targets and pathways now being studied.
Medical subject headings
- Antineoplastic Agents
- Bone Neoplasms
- Molecular Targeted Therapy
- Sarcoma
- Soft Tissue Neoplasms